Calliditas Therapeutics AB (CALT)
20.00
+1.00
(+5.25%)
USD |
NASDAQ |
May 03, 16:00
Calliditas Therapeutics Free Cash Flow (Quarterly)
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2022 | 20.59M |
| September 30, 2022 | -9.052M |
| June 30, 2022 | -22.03M |
| March 31, 2022 | -20.55M |
| December 31, 2021 | -19.16M |
| September 30, 2021 | -3.000M |
| June 30, 2021 | -15.75M |
| March 31, 2021 | -16.02M |
| December 31, 2020 | -12.41M |
| September 30, 2020 | -12.49M |
| June 30, 2020 | -6.922M |
| March 31, 2020 | -1.952M |
| Date | Value |
|---|---|
| December 31, 2019 | -4.849M |
| September 30, 2019 | 8.839M |
| June 30, 2019 | -6.117M |
| March 31, 2019 | -5.390M |
| December 31, 2018 | -5.188M |
| September 30, 2018 | -1.440M |
| June 30, 2018 | -3.967M |
| March 31, 2018 | -4.175M |
| December 31, 2017 | -2.891M |
| September 30, 2017 | -2.291M |
| June 30, 2017 | -1.386M |
| March 31, 2017 | -1.412M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-22.03M
Minimum
Jun 2022
20.59M
Maximum
Dec 2022
-8.058M
Average
-9.052M
Median
Sep 2022
Free Cash Flow (Quarterly) Benchmarks
| DBV Technologies SA | -14.04M |
| Cellectis SA | 39.44M |
| Adaptimmune Therapeutics PLC | -15.50M |
| Akari Therapeutics PLC | -- |
| Biodexa Pharmaceuticals Plc | -- |